Unlock stock picks and a broker-level newsfeed that powers Wall Street.
LSE - Delayed Quote GBp

Bioventix PLC (BVXP.L)

Compare
2,850.00
0.00
(0.00%)
At close: March 14 at 5:00:44 PM GMT
Loading Chart for BVXP.L
  • Previous Close 2,850.00
  • Open 2,800.00
  • Bid 2,800.00 x --
  • Ask 2,900.00 x --
  • Day's Range 2,800.00 - 2,900.00
  • 52 Week Range 2,700.00 - 4,800.00
  • Volume 9,570
  • Avg. Volume 4,523
  • Market Cap (intraday) 148.76M
  • Beta (5Y Monthly) 0.43
  • PE Ratio (TTM) 18.63
  • EPS (TTM) 1.53
  • Earnings Date Mar 24, 2025 - Mar 28, 2025
  • Forward Dividend & Yield 1.55 (5.44%)
  • Ex-Dividend Date Nov 7, 2024
  • 1y Target Est 5,100.00

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. It also provides contract SMAs services; and industrial and environmental biomonitoring platform, which reduces the time between sampling and results. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.

www.bioventix.com

17

Full Time Employees

June 30

Fiscal Year Ends

Recent News: BVXP.L

View More

Performance Overview: BVXP.L

Trailing total returns as of 3/14/2025, which may include dividends or other distributions. Benchmark is FTSE 100 .

YTD Return

BVXP.L
10.24%
FTSE 100
5.62%

1-Year Return

BVXP.L
38.02%
FTSE 100
11.48%

3-Year Return

BVXP.L
11.54%
FTSE 100
20.00%

5-Year Return

BVXP.L
14.03%
FTSE 100
60.87%

Compare To: BVXP.L

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BVXP.L

View More

Valuation Measures

As of 3/14/2025
  • Market Cap

    148.76M

  • Enterprise Value

    142.76M

  • Trailing P/E

    18.64

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    11.09

  • Price/Book (mrq)

    12.39

  • Enterprise Value/Revenue

    10.49

  • Enterprise Value/EBITDA

    13.29

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    59.51%

  • Return on Assets (ttm)

    49.17%

  • Return on Equity (ttm)

    67.29%

  • Revenue (ttm)

    13.61M

  • Net Income Avi to Common (ttm)

    8.1M

  • Diluted EPS (ttm)

    1.53

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    6.91M

Research Analysis: BVXP.L

View More

People Also Watch